Why Aligos Therapeutics, Inc.’s (ALGS) Stock Is Down 11.67%
As of Wednesday, April 15, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 11.67%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Aligos Therapeutics, Inc.’s (ALGS) Stock Is Down 15.56%
As of Wednesday, April 15, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 15.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aligos Therapeutics, Inc.’s (ALGS) Stock Is Up 5.81%
As of Tuesday, April 07, Aligos Therapeutics, Inc.’s ALGS share price has surged by 5.81%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Aligos Therapeutics, Inc.’s (ALGS) Stock Is Down 6.20%
As of Monday, January 12, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 6.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aligos Therapeutics, Inc.’s (ALGS) Stock Is Down 5.91%
As of Friday, January 09, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ALGS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $40.2 | $286.3 | 14% |
|
| Shares Out (Mil) | 10.4 | 54.2 | 21% |
|
| Institutional Ownership | 93.4% | 92.8% | 63% |
|
| Float (Mil) | 3.7 | 39.7 | 10% |
|
| Beta | 2.28 | 0.94 | 95% |
|
| Avg Daily Volume (000s) | 184 | 534 | 43% |
|
| Price Change (52-week) |
(27.4%) | 58.7% | 25% |
|
| Growth | ALGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 25.9% | (10.1%) | 81% |
|
| EPS (5yr) | 61.0% | 16.0% | 96 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (15.6%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 6 | |
| Current EPS | ($2.618) | ($6.578) | ($5.054) | |
| Month Ago EPS | ($2.149) | ($7.110) | ($3.989) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($2.666) | ($8.002) | ($4.191) | |
| Year/Year Chg | 1,718% | 168.5% | (13.3%) | |
| Financials | ALGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $32 | $37 | 16% |
|
| Net Income (TTM) (Mil) | ($76) | ($43) | 13% |
|
| EPS (TTM) | ($7.303) | ($1.400) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($94) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $12 | $2 | 58% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 13% |
|
| Enterprise Value (Q1) (Mil) | $19 | $160 | 11% |
|
| Valuation | ALGS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.25 | 2.77 | 31% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALGS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (180.4%) | 64.2% | 1% |
|
| Net Margin | (241.0%) | (75.9%) | 4% |
|
| ROA | (75.6%) | (47.3%) | 8% |
|
| ROE | (113.6%) | (55.0%) | 8% |
|
| Liabilities to Assets | 51.9% | 29.6% | 45% |
|
| F-Score | 3 | 2 | 18% |
|
Aligos Therapeutics, Inc. did not pass any screens on 8/20/2026.
